ABM-4095 / ABM Therap - LARVOL DELTA

A novel pMEK inhibitor ABM-4095 for the treatment of pancreatic cancer (AACR 2024) - "The only currently approved targeted therapy is erlotinib in combination with the chemotherapy drug gemcitabine...In a Miapaca-2 xenograft model, ABM-4095 showed good dose-dependent tumor inhibition as a single agent or combining with the KRAS G12C inhibitor AMG-510, and tumor regressions were observed. In summary, ABM-4095 is a potent pMEK inhibitor with a high activity against the RAS-mutant pancreatic cancer in vitro and in vivo. Detailed preclinical results will be presented."

Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Solid Tumor • BRAF • KRAS

Novel dual MEK inhibitors for RAS-mutated colorectal cancer as a single agent or in combination with known therapies including aPD-1 (SITC 2024) - "While the known MEK inhibitors such as Cobimetinib block the phospho-ERK (pERK) formation in BRAF-V600E mutated situation, their combination with selective BRAF inhibitors has been successfully used clinically, except colorectal cancer (CRC)...Targeted-therapy to KRAS-mutated CRC have been evaluated in clinical studies, such as KRAS-G12C inhibitors Sotorasib and Adagrasib...Methods Avutometinib and its close analogs such as IMM-1-104 and NST-628 are in clinical development...In a HCT116 xenograft model (human CRC cell-line with KRAS-G13D mutation), ABM-4095 dose-dependently inhibited tumor growth, similar to that of Avutometinib at its maximal-tolerant dose. In a CRC SW837 (KRAS-G12C, insensitive to Adagrasib) model, ABM-4218 showed synergic effect with Adagrasib, as well as the EGFR antibody Cetuximab...Conclusions In summary, A series of novel dual MEK inhibitors have been studied for the possible treatment of colorectal cancer by modulating the pERK level via the..."

Combination therapy • IO biomarker • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • KRAS • MAP2K1

The novel dual MEK inhibitor ABM-4095 for RAS-mutated lung cancer as a single agent or in combination with known therapies (EORTC-NCI-AACR 2024) - "While the known MEK inhibitors such as Cobimetinib block the phospho-ERK (pERK) formation in BRAF-V600E mutated situation, their combination with selective BRAF inhibitors has been successfully used clinically...Targeted-therapy to KRAS-mutated lung cancers have been extensively evaluated, resulting in the recent FDA approval of KRAS-G12C inhibitors such as Sotorasib and Adagrasib... Avutometinib and its close analogs such as IMM-1-104 and NST-628 are in clinical development...ABM-4095 showed synergic effect with erlotinib in lung cancers (KRAS-G12C H358 xenograft model)... In summary, ABM-4095 is a potent dual MEK inhibitor with activities against the RAS mutant lung cancer. ABM-4095 inhibited cell growth in vitro, and to induce tumor regression in vivo as a single agent and in combination with approved agents for the treatment of lung cancer."

Combination therapy • Lung Cancer • Oncology • Solid Tumor • KRAS